<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27417" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Polymyositis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sarwar</surname>
            <given-names>Ayesha</given-names>
          </name>
          <aff>King Edward Medical University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Dydyk</surname>
            <given-names>Alexander M.</given-names>
          </name>
          <aff>Abrazo Central Campus</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jatwani</surname>
            <given-names>Shraddha</given-names>
          </name>
          <aff>Dignity Health Mercy Medical Group</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ayesha Sarwar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alexander Dydyk declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shraddha Jatwani declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27417.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Polymyositis, a relatively uncommon autoimmune disorder, develops due to abnormal activation of cytotoxic T lymphocytes (CD8 cells) and macrophages against muscular antigens that result in rhabdomyolysis and ultimately presents as a proximal myopathy. This activity outlines the evaluation and treatment of polymyositis and highlights the role of the interprofessional team in the care of patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Review the etiology of polymyositis.</p></list-item><list-item><p>Describe the appropriate evaluation process for polymyositis.</p></list-item><list-item><p>Outline the management options for polymyositis.</p></list-item><list-item><p>Summarize the interprofessional team strategies for improving care coordination and communication to enhance the care of patients with polymyositis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27417&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27417">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27417.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Idiopathic inflammatory myopathies involve four major subtypes that include polymyositis, dermatomyositis, inclusion body myositis, and necrotizing myopathy. Bohan and Peter categorized myopathies into 7 classes.<xref ref-type="bibr" rid="article-27417.r1">[1]</xref>&#x000a0;Polymyositis, an autoimmune and chronic inflammatory myopathy, is characterized by symmetrical proximal muscle weakness due to the involvement of endomysial layers of skeletal muscles versus dermatomyositis, which involves the perimysial layers of muscles along with dermatological presentations.<xref ref-type="bibr" rid="article-27417.r2">[2]</xref>&#x000a0;</p>
        <p>Polymyositis develops over the months as compared to inclusion body myositis (IBM), which is a slowly progressive chronic myopathy developing in older individuals over a period of months to years with more severe symptoms. IBM develops secondary to either an autoimmune reaction or a degenerative process due to a persistent retroviral infection such as&#x000a0;human T-cell leukemia type 1 (HTLV-1).<xref ref-type="bibr" rid="article-27417.r3">[3]</xref>&#x000a0;Being an autoimmune disorder, polymyositis, a rheumatological disease, requires long-term treatment with steroids or immunomodulators along with the treatment of the underlying etiological factors.&#x000a0;Although this is a rare disorder, polymyositis should be a part of the differential diagnosis of patients experiencing unexplained muscle weakness, as the failure to make a diagnosis can have a significant impact on the patient's quality of life due to severe complications.</p>
      </sec>
      <sec id="article-27417.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Polymyositis (PM), an autoimmune disorder, develops due to abnormal activation of cytotoxic T lymphocytes (CD8 cells) and macrophages against muscular antigens as well as the strong extrafusal muscular expression of major histocompatibility complex 1, causing damage to the endomysium of skeletal muscles.<xref ref-type="bibr" rid="article-27417.r4">[4]</xref><xref ref-type="bibr" rid="article-27417.r5">[5]</xref>&#x000a0;Different cytokines, including interleukins, tumor necrosis factor, etc, play an important role in causing rhabdomyolysis. It mostly affects individuals already suffering from some kind of systematic disease due to viral infections, malignancies, or other autoimmune disorders. The commonly responsible viruses for polymyositis are the retroviruses human immunodeficiency virus and human T-lymphotropic virus 1, and hepatitis C virus that possibly cause this inflammatory muscle degeneration by causing endomysial damage leading to edematous swelling and nodular mass formation in the myocytes.<xref ref-type="bibr" rid="article-27417.r6">[6]</xref><xref ref-type="bibr" rid="article-27417.r7">[7]</xref>&#x000a0;</p>
        <p>Coxsackievirus is another reason for this autoimmune disorder due to the abnormal functioning of the major histocompatibility complex secondary to the release of the cytokines after damaging the intima and endothelium of blood vessels.<xref ref-type="bibr" rid="article-27417.r8">[8]</xref>&#x000a0;Another important etiological factor for polymyositis-induced rhabdomyolysis is&#x000a0;an underlying malignancy, eg, lung carcinoma, genitourinary malignancy, or lymphomas. The presence of polymyositis also increases the possibility of having carcinoma in 2 to 5 years after the diagnosis, especially non-Hodgkin lymphoma. It has the highest risk of development, followed by lung carcinoma and bladder carcinoma.<xref ref-type="bibr" rid="article-27417.r9">[9]</xref>&#x000a0;Other causes include the presence of certain human leukocyte antigen variants (A1, B8, DR3), the presence of another autoimmune disease such as celiac disease,<xref ref-type="bibr" rid="article-27417.r10">[10]</xref>&#x000a0;and the use of few medications such as&#x000a0;hydralazine, procainamide, antiepileptics, and angiotensin-converting enzyme inhibitors&#x000a0;due to&#x000a0;their ability to act as a hapten. A study reported that rarely patients on statin therapy developed polymyositis.<xref ref-type="bibr" rid="article-27417.r11">[11]</xref></p>
      </sec>
      <sec id="article-27417.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Autoimmune disorders are the leading cause of increased mortality among the middle-aged population in the United States, with varying incidence rates.<xref ref-type="bibr" rid="article-27417.r12">[12]</xref>&#x000a0;Polymyositis rarely presents in childhood and usually affects people 20 and older. Dermatomyositis, however, has a bimodal age distribution affecting the population between 5 to 15 years and 45 to 60 years.<xref ref-type="bibr" rid="article-27417.r13">[13]</xref>&#x000a0;The chances of disease development are almost double in women than in men, which is exactly the opposite of IBM. In the United States population, the rate of development of this autoimmune disorder is about&#x000a0;0.5&#x000a0;to 8.4 cases per 100,000 individuals. Having ethnic variation, it has been more commonly reported in&#x000a0;Black populations than in White.</p>
      </sec>
      <sec id="article-27417.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Pathophysiological mechanisms have been proposed to define the main reason for rhabdomyolysis in polymyositis.&#x000a0;Direct damage is caused by the cellular immune response that develops&#x000a0;as a result of abnormal activation of cytotoxic T cells (CD8) and macrophages, with some involvement of type B lymphocytes and&#x000a0;dendritic cells. Indirectly, damage can happen due to the release of&#x000a0;inflammatory mediators in circulation by the cells such as cytokines and interleukins. A study reported a significant increase in pro-inflammatory cytokine IL-21, both in the muscle and serum of affected patients, along with the increased expression of IL-21 receptors (IL-21R) in damaged muscle fibers in these patients.<xref ref-type="bibr" rid="article-27417.r14">[14]</xref>&#x000a0;T helper type 1 (Th-1) response due to the release of cytokines (tumor necrosis factor, interferon-gamma, IL-12) and T helper type 17 (Th17) response due to its pro-inflammatory mediators (interleukin [IL]-17, IL-22, and IL-6) are other potential pathogenic mechanisms for causing polymyositis.<xref ref-type="bibr" rid="article-27417.r15">[15]</xref><xref ref-type="bibr" rid="article-27417.r16">[16]</xref>&#x000a0;</p>
        <p>In addition to causing direct damage, certain cytokines such as&#x000a0;IL-1alpha and IL-17&#x000a0;also upregulate the nuclear factor kappa B signaling pathway to increase major histocompatibility complex 1 class expression.&#x000a0;NF-kappaB also damages myofibrils by affecting the myocytes' differentiating ability negatively.<xref ref-type="bibr" rid="article-27417.r17">[17]</xref>&#x000a0;Other possible pathological causes for polymyositis include damage to vascular endothelium leading to extravasation of inflammatory mediators from circulation as well as the involvement of humoral immune response depending on the presence of certain antibodies.</p>
      </sec>
      <sec id="article-27417.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Polymyositis is a chronic inflammatory disease, so multiple small foci of inflammatory and necrotic changes and regenerative nodules can be seen on biopsy.&#x000a0;Histopathological findings of polymyositis show endomysial mononuclear infiltrate consisting of mostly CD8 T cells and macrophages along with necrotic myofibrils in the early stage. Late-stage changes include occluded capillaries secondary to inflammatory changes caused by endothelial damage and increased deposition of connective tissue and extracellular matrix. Polymyositis can be differentiated from inclusion body myositis due to the presence of&#x000a0;intracytoplasmic inclusion bodies in IBM and from dermatomyositis due to&#x000a0;perimysial infiltrates of CD4 cells as well as B lymphocytes.</p>
      </sec>
      <sec id="article-27417.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The first step to diagnosing polymyositis in the early stage is to get a detailed history, including family history, medication history, and any antecedent infections. Polymyositis is a relatively challenging diagnosis due to the absence of dermatological findings compared to dermatomyositis. The following points should be asked in detail to make an accurate diagnosis.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>There is a gradual onset of myopathy with or without associated myalgia.</p>
          </list-item>
          <list-item>
            <p>There is a presence of joint pains to rule out other autoimmune disorders.</p>
          </list-item>
          <list-item>
            <p>The pelvic girdle is involved more commonly as compared to the shoulder muscles, so inquire about the difficulty in standing up from the sitting posture. Patients with upper body involvement can have difficulty combing hair, raising their arms above the head, and holding the neck upright.</p>
          </list-item>
          <list-item>
            <p>Patients having the systematic spread can complain of dysphagia due to pharyngeal or esophageal muscle involvement, breathing difficulty, or chest tightness due to infiltrative cardiomyopathy or pericarditis.</p>
          </list-item>
        </list>
        <p>
<bold>Presenting Features</bold>
</p>
        <p>The hallmark of polymyositis is a progressive disease with symmetric involvement of proximal girdle muscles (shoulder and pelvis muscles) and neck flexors&#x000a0;that can be painful at times.<xref ref-type="bibr" rid="article-27417.r2">[2]</xref>&#x000a0;Hip extensors can be involved in some patients, making it difficult for them to climb stairs or to have posture changes. Patients&#x000a0;may complain of the inability to overhead abduction or to get up from the seated position. Disease progression to distal muscles can result in abnormal fine movements such as writing and playing musical instruments. Constitutional symptoms include low-grade fever, anorexia, arthralgia, and weight loss. Polymyositis can cause interstitial lung disease (ILD), especially in anti-Jo-1 positive patients, presenting as shortness of breath and dry cough.<xref ref-type="bibr" rid="article-27417.r18">[18]</xref>&#x000a0;Other presenting complaints are chest tightness and exertional dyspnea due to restrictive cardiomyopathy, constipation or bloating due to gastrointestinal involvement, and tightening and discoloration of fingers due to the Raynaud phenomenon.</p>
        <p>The physical examination must include a complete motor and sensory examination of the affected muscles. Though the sensory examination is usually normal in these patients, motor examination reveals a decrease in power in the affected portion depending on disease severity with lost tendon reflexes in severe muscular atrophy. Patients with restrictive polymyositis can present with limited mobility of truncal muscles, especially abnormal flexion, which is called camptocormia.<xref ref-type="bibr" rid="article-27417.r19">[19]</xref>&#x000a0;The involvement of nasopharyngeal muscles can cause&#x000a0;nasal speech, while, in the presence of ILD, crackles can be heard at the lung bases. If polymyositis is associated with any malignancy, then features of that particular neoplasia can be seen, eg, lymphadenopathy in non-Hodgkin lymphoma. Skin rashes can be found in the presence of other autoimmune disorders, such as mixed connective tissue disorder.</p>
      </sec>
      <sec id="article-27417.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The multi-modal approach of hematologic and serologic testing, imaging, electromyography, nerve conduction studies, and biopsy findings is&#x000a0;used to evaluate a patient with suspected polymyositis. A complete blood count can show an elevated lymphocyte count in the majority of the patients and frequent thrombocytosis as well. The erythrocyte sedimentation rate can be elevated&#x000a0;due to chronic inflammation. Serum&#x000a0;creatine kinase (CK) levels can be up to 50 times the normal range (22 to 198 units/liter), indicating myocyte damage due to chronic inflammation. It can be of great clinical use to monitor disease progression by having serial examinations and CK monitoring.</p>
        <p>Multiple antibodies can be elevated in polymyositis, such as a non-specific antinuclear antibody (ANA), which can be positive in around 33 percent of the patients with polymyositis (PM). If ANA turns out to be positive, then specific antibody testing is done to confirm PM,&#x000a0;which is the anti-signal recognition particle in the serum. The presence of anti-aminoacyl tRNA synthetase antibodies can show the association of PM with an autoimmune syndrome&#x000a0;known&#x000a0;as anti-synthetase syndrome. This&#x000a0;is characterized by a group of varying physical presenting features such as inflammation-induced myopathy, joint pain, Raynaud's phenomenon, and fibrotic lung disease.<xref ref-type="bibr" rid="article-27417.r20">[20]</xref>&#x000a0;In the case of statin-induced PM, a unique 3-hydroxy-3-methylglutaryl coenzyme A reductase IgG immunoglobulin (anti-HMGCR) can be elevated.<xref ref-type="bibr" rid="article-27417.r21">[21]</xref>&#x000a0;</p>
        <p>Almost all the patients with PM will have abnormal electromyography (EMG) findings, such as varying amplitude and velocity of the membranous action potential and fibrillation in potentials due to membrane irritability. A vital investigation to make a definitive diagnosis of myopathy is a magnetic resonance imaging, or EMG-guided biopsy that shows perivascular and endomysial mononuclear infiltrates (cytotoxic T lymphocytes and macrophages) and areas of necrosis staining pink due to high eosin stain binding.<xref ref-type="bibr" rid="article-27417.r22">[22]</xref></p>
        <p>Imaging studies such as MRI, computed tomography scan, or ultrasonography can be useful to locate an area of muscle damage and diagnose underlying malignancy. Whole-body magnetic resonance imaging is of utmost significance in diagnosing the damaged muscular area.<xref ref-type="bibr" rid="article-27417.r23">[23]</xref>&#x000a0; If the patient presents with dysphagia, a barium swallow can be performed. In the case of lung disease, pulmonary function tests (PFTs) can be done. If PM has damaged cardiomyocytes, an electrocardiogram and echocardiography can be performed.</p>
      </sec>
      <sec id="article-27417.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Polymyositis is treated with a combination of different pharmacological and non-pharmacological modalities. Pharmacological treatment mainly includes corticosteroids. Prednisone and methylprednisolone are the most common corticosteroids used for polymyositis, with a starting dose of 1 mg/kg of prednisone a day. The steroids are tapered off gradually and not withdrawn suddenly. The second-line treatment option includes the use of immune modulators (methotrexate, azathioprine, cyclosporine) in those patients who either do not respond to steroids or develop severe adverse effects due to steroid usage. Cyclophosphamide, an immune modulator, works efficiently, especially in patients with the involvement of the pulmonary interstitium.<xref ref-type="bibr" rid="article-27417.r24">[24]</xref>&#x000a0;In the case of chronic refractory polymyositis,&#x000a0;intravenous immunoglobulins (IVIG) can be used. A study showed improvement in around 70% of the patients after using IVIG.<xref ref-type="bibr" rid="article-27417.r25">[25]</xref>&#x000a0;</p>
        <p>IVIG also shows significant improvement in patients with dysphagia due to esophageal involvement.[26] Certain biologics, such as infliximab and etanercept, have been used in treating refractory cases of PM.[27] Other therapies include tacrolimus, a calcineurin inhibitor that has proven to be beneficial in patients with&#x000a0;refractory disease with simultaneous use of prednisolone.<xref ref-type="bibr" rid="article-27417.r26">[26]</xref>&#x000a0;Mycophenolate mofetil and the anti-CD20 monoclonal antibody rituximab have also been found to be useful in treating refractory cases of polymyositis.</p>
        <p>Patients with different systems involved must be evaluated by the concerned specialty eg, a cardiologist for cardiomyopathy, a pulmonologist for ILD, a speech therapist for voice change, etc. Non-pharmacological treatment includes physical therapy of the affected muscles to prevent disuse atrophy. These patients must be advised to have supervised resistive strength training activities.<xref ref-type="bibr" rid="article-27417.r27">[27]</xref>&#x000a0;These individuals should be advised to have a diet rich in proteins that help in muscle building.</p>
      </sec>
      <sec id="article-27417.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>If a patient presents with myopathy, the following conditions must be excluded to make an absolute diagnosis.</p>
        <list list-type="bullet">
          <list-item>
            <p>Electrolyte imbalance-induced myopathy can commonly occur due to the loss of potassium, phosphate, or magnesium from the body. Hypokalemia/Hypophosphatemia can cause muscle cramps and aches, leading to a myopathic situation similar to PM.</p>
          </list-item>
          <list-item>
            <p>Another important category that must be kept in the differential is endocrinological disorders, eg, hypothyroidism or hyperthyroidism, diabetes mellitus, metabolic syndrome, etc. These hormonal disorders can weaken proximal musculature, making the clinical presentation similar to PM.</p>
          </list-item>
          <list-item>
            <p>Other autoimmune disorders should be ruled out to diagnose polymyositis. The most common differential is dermatomyositis which is easily differentiated by the dermatologic presentation and endomysial presentation on biopsy. Other disorders to keep in mind for making the diagnosis of PM are myasthenia gravis, mixed connective tissue disorder, systemic lupus erythematosus, scleroderma, iatrogenic myopathies, and myositis-induced myopathies (focal/giant cell myositis).</p>
          </list-item>
          <list-item>
            <p>A history of chronic steroid use should be taken to exclude steroid-induced myopathy or Cushing syndrome.</p>
          </list-item>
          <list-item>
            <p>Patients with a previous diagnosis of fibromyalgia or polymyalgia rheumatica can complain about muscle pain and weakness. These patients must be carefully evaluated to exclude these causes. Amyotrophic lateral sclerosis can cause myopathy, so it should be excluded as well.</p>
          </list-item>
          <list-item>
            <p>Drugs can be an important cause of myopathies, so all the drugs having a tendency for myopathy should be kept in mind, such as statins, alcohol derivates, eg, ethanol,&#x000a0;antimetabolites (vincristine), azathioprine, chloroquine/primaquine, and anti-fungal agents.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27417.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Polymyositis, being a chronic disease, is associated with a grave prognosis in the long run. In addition to causing disability and affecting the quality of life of the patient, this disease has also been found to be associated with a 10% mortality rate, especially in those who also develop cardiac dysfunction or malignant conditions.<xref ref-type="bibr" rid="article-27417.r28">[28]</xref>&#x000a0;The majority of patients usually respond to steroid therapy. This disease has the worst prognosis in patients having refractory disease, older females, Blacks, and patients having systematic involvement.</p>
      </sec>
      <sec id="article-27417.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Although polymyositis is a rare disease, it has been found to be associated with increased morbidity&#x000a0;and mortality due to its associated comorbid conditions, eg, the involvement of major vessels or the gastrointestinal tract. Patients with polymyositis have about a 2.2% risk of having myocardial infarction as compared to the general population.<xref ref-type="bibr" rid="article-27417.r29">[29]</xref>&#x000a0;Patients with polymyositis are most likely to be diagnosed with cancer within the first year following the diagnosis of polymyositis, so age and gender-specific evaluation for malignancy should be done in all the patients with PM.<xref ref-type="bibr" rid="article-27417.r30">[30]</xref>&#x000a0;According to a study, the presence of a high neutrophil/lymphocyte ratio in patients above the age of 60 years greatly increases the risk of having carcinoma of the lung/bladder or non-Hodgkin lymphoma.<xref ref-type="bibr" rid="article-27417.r31">[31]</xref></p>
        <p>Polymyositis affects the distal musculature of the esophagus in the late stage of the disease in up to 70% of the patients, leading to the inability to swallow, as well as regurgitation problems that can cause aspiration pneumonia.<xref ref-type="bibr" rid="article-27417.r32">[32]</xref>&#x000a0;The involvement of the lungs can increase the mortality rate due to having an adverse impact on the quality of life. The presence of PM in the females of the child-bearing age group can result in fetal loss in the case of active disease. PM can induce a hypercoagulable state in the plasma, leading to an increased incidence of thromboembolism.<xref ref-type="bibr" rid="article-27417.r33">[33]</xref>&#x000a0;An increase in the risk of development of amyotrophic lateral sclerosis was also&#x000a0;observed in a study in patients with PM.<xref ref-type="bibr" rid="article-27417.r34">[34]</xref>&#x000a0;Osteoporosis risk has been found to be elevated in patients with PM.<xref ref-type="bibr" rid="article-27417.r35">[35]</xref></p>
      </sec>
      <sec id="article-27417.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Since&#x000a0;polymyositis can cause multiple comorbid conditions, it is mandatory to guide the patients to lessen their suffering properly. The following points should be explained to patients to prevent future consequences.</p>
        <list list-type="order">
          <list-item>
            <p>Guide patients to prevent extreme cold weather conditions due to potential chances of cold-induced necrosis of extremities due to Raynaud phenomenon-induced vascular obliteration/spasm.</p>
          </list-item>
          <list-item>
            <p>Patients with esophageal motility disorder should be educated to avoid lying down immediately after meals.</p>
          </list-item>
          <list-item>
            <p>Prophylactic supplements containing calcium and vitamin D should be started early to prevent disease or steroid-induced osteoporosis.</p>
          </list-item>
          <list-item>
            <p>Detailed information should be provided to the patient if there is a possibility of having any underlying malignancy in high-risk candidates, such as older male patients having broad systematic involvement.<xref ref-type="bibr" rid="article-27417.r36">[36]</xref></p>
          </list-item>
          <list-item>
            <p>The importance of physical training should be emphasized.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27417.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>A strong clinician-patient relationship is mandatory to improve healthcare outcomes, along with good communication among an interprofessional team, which includes a rheumatologist, neurologist, gastroenterologist, pulmonologist, primary clinician, physiotherapist, dietician, and nurses. Without proper management, the morbidity and mortality from polymyositis&#x000a0;are high. However, successful diagnosis and treatment at the initial stage can&#x000a0;help patients live longer.</p>
      </sec>
      <sec id="article-27417.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27417&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27417">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/polymyositis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27417">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27417/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27417">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27417.s16">
        <title>References</title>
        <ref id="article-27417.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bohan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>History and classification of polymyositis and dermatomyositis.</article-title>
            <source>Clin Dermatol</source>
            <year>1988</year>
            <season>Apr-Jun</season>
            <volume>6</volume>
            <issue>2</issue>
            <fpage>3</fpage>
            <page-range>3-8</page-range>
            <pub-id pub-id-type="pmid">3293742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strauss</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Gonzalez-Buritica</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Khamashta</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>GR</given-names>
              </name>
            </person-group>
            <article-title>Polymyositis-dermatomyositis: a clinical review.</article-title>
            <source>Postgrad Med J</source>
            <year>1989</year>
            <month>Jul</month>
            <volume>65</volume>
            <issue>765</issue>
            <fpage>437</fpage>
            <page-range>437-43</page-range>
            <pub-id pub-id-type="pmid">2690042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalakas</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies.</article-title>
            <source>Nat Clin Pract Neurol</source>
            <year>2006</year>
            <month>Aug</month>
            <volume>2</volume>
            <issue>8</issue>
            <fpage>437</fpage>
            <page-range>437-47</page-range>
            <pub-id pub-id-type="pmid">16932602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kamiya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mizoguchi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Takamura</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kimura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kawahata</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kohsaka</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A new in vitro model of polymyositis reveals CD8+ T cell invasion into muscle cells and its cytotoxic role.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2020</year>
            <month>Jan</month>
            <day>01</day>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>224</fpage>
            <page-range>224-232</page-range>
            <pub-id pub-id-type="pmid">31257434</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Karpati</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pouliot</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Carpenter</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Expression of immunoreactive major histocompatibility complex products in human skeletal muscles.</article-title>
            <source>Ann Neurol</source>
            <year>1988</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>64</fpage>
            <page-range>64-72</page-range>
            <pub-id pub-id-type="pmid">3278673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richardson</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rojas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Holodniy</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Herndier</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Multinodular polymyositis in a patient with human immunodeficiency and hepatitis C virus coinfection.</article-title>
            <source>Muscle Nerve</source>
            <year>2001</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>433</fpage>
            <page-range>433-7</page-range>
            <pub-id pub-id-type="pmid">11353433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalakas</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pezeshkpour</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Gravell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Polymyositis associated with AIDS retrovirus.</article-title>
            <source>JAMA</source>
            <year>1986</year>
            <month>Nov</month>
            <day>07</day>
            <volume>256</volume>
            <issue>17</issue>
            <fpage>2381</fpage>
            <page-range>2381-3</page-range>
            <pub-id pub-id-type="pmid">3464769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000f3;mez Rodr&#x000ed;guez</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ib&#x000e1;&#x000f1;ez Ru&#x000e1;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez Rodr&#x000ed;guez</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Coxsackie virus infection associated with myositis and polyarthritis].</article-title>
            <source>An Med Interna</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>90</fpage>
            <page-range>90-2</page-range>
            <pub-id pub-id-type="pmid">18432367</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sigurgeirsson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Pukkala</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mellemkjaer</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Airio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Felson</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study.</article-title>
            <source>Lancet</source>
            <year>2001</year>
            <month>Jan</month>
            <day>13</day>
            <volume>357</volume>
            <issue>9250</issue>
            <fpage>96</fpage>
            <page-range>96-100</page-range>
            <pub-id pub-id-type="pmid">11197446</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shapiro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Blanco</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Neurological Complications of Gastrointestinal Disease.</article-title>
            <source>Semin Pediatr Neurol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-53</page-range>
            <pub-id pub-id-type="pmid">28779865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grable-Esposito</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Katzberg</surname>
                <given-names>HD</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Amato</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Immune-mediated necrotizing myopathy associated with statins.</article-title>
            <source>Muscle Nerve</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>185</fpage>
            <page-range>185-90</page-range>
            <pub-id pub-id-type="pmid">19813188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cooper</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Stroehla</surname>
                <given-names>BC</given-names>
              </name>
            </person-group>
            <article-title>The epidemiology of autoimmune diseases.</article-title>
            <source>Autoimmun Rev</source>
            <year>2003</year>
            <month>May</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>119</fpage>
            <page-range>119-25</page-range>
            <pub-id pub-id-type="pmid">12848952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marie</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hatron</surname>
                <given-names>PY</given-names>
              </name>
              <name>
                <surname>Levesque</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hachulla</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hellot</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Michon-Pasturel</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Courtois</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Devulder</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Influence of age on characteristics of polymyositis and dermatomyositis in adults.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>1999</year>
            <month>May</month>
            <volume>78</volume>
            <issue>3</issue>
            <fpage>139</fpage>
            <page-range>139-47</page-range>
            <pub-id pub-id-type="pmid">10352646</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>CZ</given-names>
              </name>
            </person-group>
            <article-title>Upregulation of Interleukin 21 and Interleukin 21 Receptor in Patients with Dermatomyositis and Polymyositis.</article-title>
            <source>Chin Med J (Engl)</source>
            <year>2017</year>
            <month>Sep</month>
            <day>05</day>
            <volume>130</volume>
            <issue>17</issue>
            <fpage>2101</fpage>
            <page-range>2101-2106</page-range>
            <pub-id pub-id-type="pmid">28836555</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Allenbach</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Chaara</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rosenzwajg</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Six</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Prevel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mingozzi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wanschitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Musset</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Charuel</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Eymard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Salomon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Duyckaerts</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maisonobe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dubourg</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Herson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Klatzmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Benveniste</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Th1 response and systemic treg deficiency in inclusion body myositis.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>e88788</fpage>
            <pub-id pub-id-type="pmid">24594700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moran</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Mastaglia</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications.</article-title>
            <source>Neuromuscul Disord</source>
            <year>2014</year>
            <month>Nov</month>
            <volume>24</volume>
            <issue>11</issue>
            <fpage>943</fpage>
            <page-range>943-52</page-range>
            <pub-id pub-id-type="pmid">25052503</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Creus</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>De Paepe</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>De Bleecker</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Idiopathic inflammatory myopathies and the classical NF-kappaB complex: current insights and implications for therapy.</article-title>
            <source>Autoimmun Rev</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>627</fpage>
            <page-range>627-31</page-range>
            <pub-id pub-id-type="pmid">19232550</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schnabel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hellmich</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gross</surname>
                <given-names>WL</given-names>
              </name>
            </person-group>
            <article-title>Interstitial lung disease in polymyositis and dermatomyositis.</article-title>
            <source>Curr Rheumatol Rep</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-105</page-range>
            <pub-id pub-id-type="pmid">15760588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuo</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Vullaganti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jimenez-Shahed</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kwan</surname>
                <given-names>JY</given-names>
              </name>
            </person-group>
            <article-title>Camptocormia as a presentation of generalized inflammatory myopathy.</article-title>
            <source>Muscle Nerve</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>40</volume>
            <issue>6</issue>
            <fpage>1059</fpage>
            <page-range>1059-63</page-range>
            <pub-id pub-id-type="pmid">19750541</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Satoh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ceribelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Calise</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>EK</given-names>
              </name>
            </person-group>
            <article-title>A Comprehensive Overview on Myositis-Specific Antibodies: New and Old Biomarkers in Idiopathic Inflammatory Myopathy.</article-title>
            <source>Clin Rev Allergy Immunol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-19</page-range>
            <pub-id pub-id-type="pmid">26424665</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mammen</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Statin-Associated Autoimmune Myopathy.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Feb</month>
            <day>18</day>
            <volume>374</volume>
            <issue>7</issue>
            <fpage>664</fpage>
            <page-range>664-9</page-range>
            <pub-id pub-id-type="pmid">26886523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chahin</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Engel</surname>
                <given-names>AG</given-names>
              </name>
            </person-group>
            <article-title>Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM.</article-title>
            <source>Neurology</source>
            <year>2008</year>
            <month>Feb</month>
            <day>05</day>
            <volume>70</volume>
            <issue>6</issue>
            <fpage>418</fpage>
            <page-range>418-24</page-range>
            <pub-id pub-id-type="pmid">17881720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elessawy</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Abdelsalam</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Abdel Razek</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tharwat</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Whole-body MRI for full assessment and characterization of diffuse inflammatory myopathy.</article-title>
            <source>Acta Radiol Open</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>9</issue>
            <fpage>2058460116668216</fpage>
            <pub-id pub-id-type="pmid">27708860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimojima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Matsuda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kishida</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>Effective Use of Calcineurin Inhibitor in Combination Therapy for Interstitial Lung Disease in Patients With Dermatomyositis and Polymyositis.</article-title>
            <source>J Clin Rheumatol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>87</fpage>
            <page-range>87-93</page-range>
            <pub-id pub-id-type="pmid">28225510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cherin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pelletier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Teixeira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Laforet</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Genereau</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Maisonobe</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Eymard</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Herson</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients.</article-title>
            <source>Arthritis Rheum</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>467</fpage>
            <page-range>467-74</page-range>
            <pub-id pub-id-type="pmid">11840450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ueno</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Shimojima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kishida</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sekijima</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>SI</given-names>
              </name>
            </person-group>
            <article-title>Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis.</article-title>
            <source>Int J Rheum Dis</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>19</volume>
            <issue>12</issue>
            <fpage>1322</fpage>
            <page-range>1322-1330</page-range>
            <pub-id pub-id-type="pmid">27457756</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexanderson</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Exercise: an important component of treatment in the idiopathic inflammatory myopathies.</article-title>
            <source>Curr Rheumatol Rep</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-24</page-range>
            <pub-id pub-id-type="pmid">15760590</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bronner</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>van der Meulen</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>de Visser</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kalmijn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Venrooij</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Voskuyl</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Dinant</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Linssen</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Wokke</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Hoogendijk</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Long-term outcome in polymyositis and dermatomyositis.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>65</volume>
            <issue>11</issue>
            <fpage>1456</fpage>
            <page-range>1456-61</page-range>
            <pub-id pub-id-type="pmid">16606652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rai</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Sayre</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Avi&#x000f1;a-Zubieta</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Risk of myocardial infarction and ischaemic stroke in adults with polymyositis and dermatomyositis: a general population-based study.</article-title>
            <source>Rheumatology (Oxford)</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>55</volume>
            <issue>3</issue>
            <fpage>461</fpage>
            <page-range>461-9</page-range>
            <pub-id pub-id-type="pmid">26424835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YT</given-names>
              </name>
            </person-group>
            <article-title>Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2010</year>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>R70</fpage>
            <pub-id pub-id-type="pmid">20398365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nicoletis</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pasco</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Maillot</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Goupille</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Corcia</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Grammatico-Guillon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Machet</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>High pre-treatment neutrophil-to-lymphocyte ratio in patients with dermatomyositis/polymyositis predicts an increased risk of cancer.</article-title>
            <source>Eur J Dermatol</source>
            <year>2020</year>
            <month>Apr</month>
            <day>10</day>
            <pub-id pub-id-type="pmid">32281931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Merieux</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Verity</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Clements</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Paulus</surname>
                <given-names>HE</given-names>
              </name>
            </person-group>
            <article-title>Esophageal abnormalities and dysphagia in polymyositis and dermatomyositis.</article-title>
            <source>Arthritis Rheum</source>
            <year>1983</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>8</issue>
            <fpage>961</fpage>
            <page-range>961-8</page-range>
            <pub-id pub-id-type="pmid">6882490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carruthers</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Sayre</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Avi&#x000f1;a-Zubieta</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study.</article-title>
            <source>Ann Rheum Dis</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>75</volume>
            <issue>1</issue>
            <fpage>110</fpage>
            <page-range>110-6</page-range>
            <pub-id pub-id-type="pmid">25193998</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tseng</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>TT</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>WY</given-names>
              </name>
              <name>
                <surname>Hsieh</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Yen</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Increased Incidence of Amyotrophic Lateral Sclerosis in Polymyositis: A Nationwide Cohort Study.</article-title>
            <source>Arthritis Care Res (Hoboken)</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>69</volume>
            <issue>8</issue>
            <fpage>1231</fpage>
            <page-range>1231-1237</page-range>
            <pub-id pub-id-type="pmid">27723283</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Muo</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Sung</surname>
                <given-names>FC</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Kao</surname>
                <given-names>CH</given-names>
              </name>
            </person-group>
            <article-title>Increased osteoporosis risk in dermatomyositis or polymyositis independent of the treatments: a population-based cohort study with propensity score.</article-title>
            <source>Endocrine</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <page-range>86-92</page-range>
            <pub-id pub-id-type="pmid">26429781</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27417.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis.</article-title>
            <source>PLoS One</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>e94128</fpage>
            <pub-id pub-id-type="pmid">24713868</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
